|Bid||1,500.00 x 175400|
|Ask||1,525.00 x 417900|
|Day's Range||1,517.50 - 1,544.50|
|52 Week Range||1,444.00 - 1,724.50|
|PE Ratio (TTM)||38.96|
|Forward Dividend & Yield||1.01 (5.14%)|
|1y Target Est||N/A|
Gene therapy is designed to deliver a one-off cure for the patient and drugmakers are typically asking a hefty price that is comparable to the combined costs of alternative life-long treatment. Britain's National Institute for Health and Care Excellence (NICE) said in draft guidance published on Friday that Strimvelis gene therapy used against adenosine deaminase deficiency, or ADA-SCID, improves overall survival compared with standard stem cell transplant therapy.
U.S. regulators have approved a new, more effective vaccine to prevent painful shingles, which is caused by the chickenpox virus.
Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck & Co (MRK.N). The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters data. Glaxo said the U.S. Centers for Disease Control and Prevention's advisory committee on immunization practices is expected to vote on a recommendation for the use of Shingrix at its meeting on Wednesday.
The U.S. Food and Drug Administration approved GlaxoSmithKline's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday. Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck & Co. The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters data.
The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .
As money rushes into China’s fledgling biotechnology sector, Eli Lilly & Co. and other foreign drugmakers are scaling back.
LONDON/SHANGHAI (Reuters) - Investors are betting on China's potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West. Shares in firms such as Chi-Med (HCM.L), Beigene (BGNE.O) and Zai Lab (ZLAB.O) have soared on international markets this year, fuelled by hopes for their drugs and recent reforms to China's regulatory system that should speed up approvals. "It's almost a coming out party for China biotech," said Christian Hogg, chief executive of Hutchison China MediTech or Chi-Med, which presented promising data at a global medical congress this week on a lung cancer drug it discovered in China and is developing with AstraZeneca (AZN.L).
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.
(Reuters) - Canadian health regulators have approved GlaxoSmithKline's (GSK.L) key shingles vaccine, the company said on Friday. Shingrix, the British pharma company's shingles vaccine for people aged ...
Pharma companies are recruiting technologists to help speed up their drug discovery and development processes.
The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...
The move comes as Germany's Merck KGaA (MRCG.DE) is also looking to divest its non-prescription products, including brands such as Seven Seas vitamins, which could be worth around $4.5 billion. As ageing populations and health-conscious consumers drive demand for self-medication, the fragmented consumer health sector has proved a fertile ground for deal-making in recent years. Pfizer's consumer healthcare business, whose brands include painkiller Advil and lip balm Chapstick, had revenue of about $3.4 billion in 2016.
Prime Minister Theresa May will meet GlaxoSmithKline, Vodafone and HSBC and other major companies on Monday to hear what they want from talks on Britain's relationship with the EU after Brexit. Businesses have become increasingly alarmed by the slow progress of negotiations and the prospect that the country could crash out of the trading bloc without a deal in 2019.
British shares edged higher on Friday and held to their highest level in two months as political uncertainties linked to Theresa's May's premiership pushed the pound lower, giving a boost to dollar-earning groups such as pharma stocks. The FTSE 100 index (.FTSE) closed 0.2 percent up at 7,522.87 points, with Britain's pound on track for its worst week in a year as the Prime Minister hit back at a plot to topple her, saying she would provide "calm leadership" to the country. "The talk of a leadership plot against the Prime Minister is eroding the pound's value and propping up the FTSE 100," CMC Markets analyst David Madden wrote in a note to clients.
As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.
Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review. Drugmakers argue the curbs, imposed earlier this year, have the potential to cause significant delays for patients waiting for treatment for a range of conditions, including for cancer, heart disease and diabetes. The Association of the British Pharmaceutical Industry (ABPI) said on Thursday, however, that its board had agreed unanimously not to appeal after a High Court judge turned down its review application on Wednesday.
GlaxoSmithKline’s (GSK) Consumer Healthcare segment has improved its supply chain over the last few years while adding new products to the portfolio.
Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives GlaxoSmithKline Plc a score of 63. Our analysis is based on comparing GlaxoSmithKline Plc with the following peers – AstraZeneca PLC, Shire PLC, Hikma Pharmaceuticals Plc and Consort Medical Plc (AZN-GB, SHP-GB, HIK-GB and CSRT-GB). Investment Outlook GlaxoSmithKline Plc has a fundamental score of 63 and has ... Read more (Read more...)
HIV products reported a 29.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16, driven by the strong performances of Tivicay and Triumeq.